$2.50
(Market cap
$555,225 Mln
Recently Viewed
Clear AllMarket cap
$555,225 Mln
Revenue (TTM)
$96,362 Mln
P/E Ratio
26.7
P/B Ratio
6.8
Div. Yield
2.3 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$15,805 Mln
ROE
0.4 %
ROCE
22.6 %
Industry P/E
24.41
EV/EBITDA
17.4
Debt to Equity
0.5
Book Value
$--
EPS
$8.6
Face value
--
Shares outstanding
2,407,216,971
CFO
$214,121.00 Mln
EBITDA
$225,943.00 Mln
Net Profit
$168,674.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| 11.1 | -4.4 | 0.9 | 47.4 | 12.0 | 7.0 | 7.4 |
|
BSE Sensex
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P 100
| 2.7 | 15.1 | 3.4 | 31.9 | 22.9 | 13.2 | 14.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
| 43.1 | -7.7 | -11.3 | 3.3 | 8.7 | 7.9 | 13.0 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Johnson & Johnson (JNJ)
|
229.9 | 555,224.5 | 96,362.0 | 21,040.0 | 20.2 | 26.2 | 26.7 | 6.8 |
| 12.9 | 4,083.2 | 2,323.3 | 44.1 | 12.3 | -- | 58.2 | 105.4 | |
| 0.5 | 22.3 | 4.2 | -3.6 | -55.0 | -0 | -- | 1.0 | |
| 0.4 | 18.7 | 71.3 | -28.5 | -22.3 | -137 | -- | 1.1 | |
| 3.1 | 1,044.3 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.1 | |
| 8.2 | 5,383.4 | 7,682.7 | 438.7 | 15.9 | 7.5 | 11.5 | 0.9 | |
| 0.1 | 101.7 | 0.0 | -17.4 | -- | -- | -- | 14.5 | |
| 46.6 | 110,281.0 | 47,354.0 | 7,555.0 | 19.6 | 10.3 | 19.8 | 1.3 | |
| 1.0 | 4.7 | 36.0 | -6.9 | -12.9 | -29.4 | -- | 0.2 |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative... Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey. Read more
CEO & Chairman
Mr. Joaquin Duato
CEO & Chairman
Mr. Joaquin Duato
Headquarters
New Brunswick, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Johnson & Johnson (JNJ) is $229.85 (NYSE) as of 30-Apr-2026 16:15 EDT. Johnson & Johnson (JNJ) has given a return of 11.98% in the last 3 years.
The P/E ratio of Johnson & Johnson (JNJ) is 26.73 times as on 24-Apr-2026, a 10 premium to its peers’ median range of 24.41 times.
The P/B ratio of Johnson & Johnson (JNJ) is 6.84 times as on 24-Apr-2026, a 22 premium to its peers’ median range of 5.60 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.83
|
6.19
|
|
2024
|
24.95
|
4.91
|
|
2023
|
10.84
|
5.54
|
|
2022
|
26.23
|
6.13
|
|
2021
|
21.88
|
6.17
|
The 52-week high and low of Johnson & Johnson (JNJ) are Rs 251.71 and Rs 146.12 as of 01-May-2026.
Johnson & Johnson (JNJ) has a market capitalisation of $ 555,225 Mln as on 24-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Johnson & Johnson (JNJ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.